QLS12010

DRUG4 trials

Sponsors

Shanghai Qilu Pharmaceutical Research and Development Center LTD, Qilu Pharmaceutical Co., Ltd.

Conditions

Adults With Moderate-to-severe Hidradenitis SuppurativaAtopic DermatitisHidradenitis Suppurativa (HS)Moderate-to-severe Atopic DermatitisRheumatoid Arthritis (RA)

Phase 1

A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients

RecruitingNCT06946641

Shanghai Qilu Pharmaceutical Research and Development Center LTDAtopic Dermatitis, Hidradenitis Suppurativa (HS), Rheumatoid Arthritis (RA)

Start: 2025-03-31End: 2026-04-30Target: 102Updated: 2025-07-31

Phase 2

A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis

Not yet recruitingNCT07344051

Qilu Pharmaceutical Co., Ltd.Moderate-to-severe Atopic Dermatitis

Start: 2026-04-05End: 2027-09-30Target: 160Updated: 2026-01-15

QLS12010 in Participants With Moderate-to-severe Rheumatoid Arthritis

Not yet recruitingNCT07377773

Qilu Pharmaceutical Co., Ltd.Rheumatoid Arthritis (RA)

Start: 2026-03-05End: 2028-06-05Target: 180Updated: 2026-02-02

QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis Suppurativa

Not yet recruitingNCT07417917

Qilu Pharmaceutical Co., Ltd.Adults With Moderate-to-severe Hidradenitis Suppurativa

Start: 2026-04-01End: 2028-05-01Target: 102Updated: 2026-02-18